The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...

In a new study published in Nature Communications, a research team at the University of Oslo have examined how cancer cells ...

A South Coast teenager is in the fight of his life, and his mother is appealing to the public to help by registering to ...

Cancer researchers are making strides in efforts to use genetic profiling to develop a more precise understanding of the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the combination regimen of Venclexta® (venetoclax) ...

Dr. Ashkan Emadi, principal investigator of a first-in-world phase 2 clinical trial evaluating subcutaneous Blincyto (blinatumomab) for CD19-positive mixed phenotype acute leukemia, sat down for an ...

Getting a diagnosis of leukemia can feel overwhelming. But multiple treatment options and support organizations can help you on your journey after diagnosis. Leukemia is a type of cancer that affects ...

Tony Garcia, who survived leukemia as a child back in the 1970s and '80s when a diagnosis was practically a death sentence, has written a book about the experience. "My Childhood Cut Short — ...

Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, ...